Jade Biosciences, Inc. Common Stock (JBIO) Stock
Fundamentals
Source: third-party data provider, as of October 15, 2026
Compare with JBIO
Technical indicators
- RSI 14
- 28.88
- MACD 12/26/9
- -1.33
- EMA 9 of MACD
- -1.47
- MACD histogram
- 0.14
- SMA 50
- $18.49
- Price below SMA 50
- EMA 50
- $17.10
- Price below EMA 50
- SMA 200
- $18.23
- Price below SMA 200
- EMA 200
- $17.16
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About Jade Biosciences, Inc. Common Stock
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Tom Frohlich | President, CEO & Director | 1976 |
| Mr. Bradford D. Dahms Ph.D. | CFO & Treasurer | 1989 |
| Dr. Andrew James King BVMS, D.V.M., Ph.D. | President of Research & Development | 1980 |
| Ms. Elizabeth Balta J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Ms. Lori Stewart | Senior Vice President of People | — |
| Mr. Jonathan Quick | Senior Vice President of Finance | — |
| Ms. Valerie Fauvelle | Senior Vice President of Regulatory & Quality | — |
| Ms. Amy Sullivan | Senior Vice President of Development Operations | — |
| Ms. Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | — |
| Dr. Edward R. Conner M.D. | Chief Medical Officer | 1973 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 15, 2026
Technical indicators
- RSI 14
- 28.88
- MACD 12/26/9
- -1.33
- EMA 9 of MACD
- -1.47
- MACD histogram
- 0.14
- SMA 50
- $18.49
- Price below SMA 50
- EMA 50
- $17.10
- Price below EMA 50
- SMA 200
- $18.23
- Price below SMA 200
- EMA 200
- $17.16
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $47.00
- Average
- $59.67
- High
- $77.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.6 | +52.3 | -13.2 | +19.5 | -9.4 | +11.5 | -33.2 | -2.4 |




